RESEARCH STATUS
Rethiamine research status and regulatory disclosure
Rethiamine™, Reta-B1™ and RetaBone™ are complementary identities for one proprietary Panacea Bio Chem research formulation: 5 mg retatrutide and 20 mg thiamine—vitamin B1—presented as a dual-layer Peptourbillon™ inside the lyophilised chamber of Lyoprester SS™, with a separate 0.5 mL P-EARLs™ reconstitution chamber.
Universal regulatory and scientific notice
The information presented on this website describes an investigational pharmaceutical formulation concept and associated scientific research. Retatrutide remains an investigational molecule and is not presented here as an approved product available for public use. Rethiamine™, Reta-B1™ and RetaBone™ have not been clinically established for preventing or treating vitamin deficiency, obesity, neurological disease, muscle loss, bone loss or any other condition. The proposed 5 mg retatrutide and 20 mg thiamine composition is a proprietary Panacea Bio Chem research formulation subject to analytical, pharmaceutical, toxicological, regulatory and clinical evaluation. This website does not provide medical advice and does not encourage self-administration or the acquisition of unapproved medicines.
Investigational status, precisely
- Rethiamine is a research formulation under development — not a marketed, authorised or approved product in any jurisdiction.
- Retatrutide is an investigational molecule developed by Eli Lilly and Company. Panacea Bio Chem has no affiliation with the developer of retatrutide.
- The thiamine component is a formulation-development inclusion; the precise pharmaceutical salt and thiamine-equivalent basis will be declared in the final analytical specification.
- No clinical evaluation of the combined formulation has been performed or claimed by Panacea Bio Chem.
Where retatrutide itself stands
As of the last evidence search, the retatrutide phase-3 programme has reported five positive readouts (TRIUMPH-1 through TRIUMPH-4 and TRANSCEND-T2D-1), and the sponsor has stated it plans a BLA submission to FDA in Q1 2027 (sponsor announcement, 2026-07-23 ↗). The weight-loss readouts come with a cardiovascular datapoint that this site reports at equal prominence: TRIUMPH-3’s neutral MACE-3 hazard ratio of 1.12 (95% CI 0.64-1.96) in participants with severe obesity and established cardiovascular disease, with the dedicated TRIUMPH-Outcomes trial ↗ still to define long-term outcomes. A planned submission is not an approval; retatrutide remains investigational.
No medical advice
Nothing on this website is medical advice, a dosing instruction or an encouragement to acquire or use unapproved medicines. Individuals with questions about weight-management pharmacotherapy or micronutrient status should consult a qualified clinician who knows their history. See the editorial policy for how this site selects and presents evidence.